High-throughput lipid library screening to identify LNP formulations matched to your payload, delivery target, and early application goal.
Lipid nanoparticle performance is highly sensitive to lipid composition, payload chemistry, formulation conditions, and downstream biological context. A formulation that works well for one mRNA, siRNA, ASO, or protein-coding construct may show reduced encapsulation, poor cellular activity, altered tissue distribution, or insufficient storage robustness when applied to another payload. BOC Sciences provides LNP lipid library screening services for RNA drug platforms, early payload adaptation projects, tissue delivery optimization programs, and biotech teams seeking rationally ranked candidate LNP formulations. Through miniaturized preparation, multi-condition formulation matrices, physicochemical profiling, functional delivery readouts, and stability comparison, we help clients understand how ionizable lipid structure, helper lipid identity, cholesterol ratio, PEG-lipid content, N/P ratio, and mixing parameters influence delivery-relevant outcomes.
BOC Sciences provides composition-focused LNP lipid library screening services to help RNA drug developers and biotech teams identify formulation candidates that better match their payload properties, delivery goals, and early application scenarios. Instead of relying on a single benchmark formulation, we compare multiple lipid classes and molar ratio windows in parallel, generating side-by-side data on particle assembly, encapsulation, colloidal quality, delivery activity, tissue-facing behavior, and formulation stability.
Ionizable lipids are often the primary performance-driving component in RNA-loaded LNPs, influencing payload encapsulation, endosomal escape, cellular activity, and tissue distribution tendencies. We screen structurally diverse ionizable lipid candidates under matched formulation backgrounds to identify compositions that provide a stronger fit for specific RNA payloads or delivery objectives.
Helper lipids regulate membrane packing, particle morphology, fusion tendency, and intracellular release behavior. We compare helper lipid libraries to determine how membrane-shaping components influence both physical formulation quality and functional delivery output.
Cholesterol and sterol-like lipids play a major role in LNP structural integrity, membrane rigidity, payload retention, and serum-facing stability. We screen cholesterol ratio windows and alternative sterol structures to help clients understand how sterol chemistry affects both formulation robustness and delivery performance.
PEG-lipids strongly influence particle size control, aggregation resistance, surface shielding, protein adsorption, cell interaction, and circulation-facing behavior. BOC Sciences screens PEG-lipid structures and molar ratios to identify a practical balance between colloidal stability and functional delivery.
Functionalized lipids can introduce ligand-mediated cell interaction, tissue-facing selectivity, imaging compatibility, or responsive behavior into LNP systems. We screen functionalized lipid panels to evaluate whether surface modification improves target-cell association while preserving particle quality and payload activity.
For early discovery programs seeking differentiated LNP behavior, BOC Sciences supports screening of advanced structural lipid classes such as degradable lipids, dendritic lipids, multi-tail lipids, branched lipids, ionizable-helper hybrid lipids, and environmentally responsive lipid structures.
Effective lipid library screening is not just a larger formulation list. It requires a staged strategy that filters candidates using complementary physicochemical, biological, and stability readouts so that the final shortlist is scientifically defensible and practical for follow-up work.
Move beyond single-formulation testing. Use structured lipid library screening to compare delivery efficiency, particle quality, stability, and target-facing performance side by side.
BOC Sciences provides an integrated LNP lipid library screening workflow that connects computational lipid prioritization, high-throughput formulation preparation, functional delivery comparison, and exploratory biodistribution assessment. This staged strategy helps clients move from a broad lipid design space to a focused candidate list supported by particle quality data, payload delivery readouts, and early tissue-facing performance indicators.
| Screening Stage | Service Segments | Key Outputs |
|---|---|---|
| In Silico Virtual Screening | Candidate lipid structures are pre-screened using molecular dynamics simulation, QSAR modeling, structure-property prediction, pKa estimation, hydrophobic tail analysis, and preliminary lipid-payload interaction assessment. | Prioritized lipid candidate list, preliminary SAR map, structural feature comparison, and recommended lipid subgroups for experimental screening. |
| High-Throughput Microfluidic Formulation Screening | Hundreds of lipid formulations can be prepared in parallel using miniaturized or microfluidic-compatible workflows. Screening variables may include ionizable lipid type, helper lipid ratio, sterol content, PEG-lipid level, N/P ratio, buffer pH, flow rate ratio, and post-mixing dilution conditions. | Particle size, PDI, encapsulation efficiency, zeta potential when needed, formulation recovery, and first-pass physical stability dataset. |
| In Vitro Functional Matrix Screening | Functional delivery is evaluated across selected cell systems such as HepG2 cells, dendritic cells, primary cells, immune-relevant cells, or target-associated cell models. Readouts can include reporter expression, siRNA knockdown, uptake, intracellular localization, and activity-to-viability comparison. | Cell-specific transfection efficiency ranking, functional activity matrix, uptake versus delivery comparison, and shortlist of candidates for confirmatory testing. |
| In Vivo Proof-of-Concept Screening | Selected LNP candidates can be compared in small animal research models, including mouse or rat models, to evaluate biodistribution, tissue signal intensity, payload activity trend, target-to-nontarget exposure pattern, and preliminary dose-response behavior. | Tissue distribution dataset, preliminary ED50/IC50 estimation when applicable, target-tissue ranking, and recommended lead candidates for further formulation optimization. |
Many early LNP projects stall because one benchmark formulation is expected to work across different payloads and delivery goals. Our screening services are built to uncover why performance shifts and which composition variables matter most.
✔ Payload Transfer Failure
A reporter RNA formulation may lose performance when switched to a longer, more structured, or chemically modified payload. We compare lipid composition and N/P ratio windows to identify formulations that match the real payload rather than the model cargo.
✔ Weak Functional Delivery Despite Good Encapsulation
High encapsulation does not guarantee cytosolic availability. We combine particle profiling with nanoparticle in vitro evaluation to distinguish retained payload from biologically useful delivery.
✔ Over-Reliance on One Lipid Composition
A single established lipid background may hide better options. We evaluate ionizable lipid families, helper lipid choices, and PEG-lipid levels to reveal formulation-performance relationships.
✔ Tissue Signal Not Matching the Intended Goal
Composition-driven differences can shift protein corona formation, organ exposure, and cell association. We design screens that compare target-facing and off-target-facing readouts rather than relying only on total uptake.
✔ Stability Loss After Candidate Selection
Some highly active formulations show rapid size drift, leakage, or aggregation after storage or dilution. We include stability-facing readouts early so that the final shortlist is more practical for downstream development.
✔ Difficult Data Interpretation Across Many Formulations
Large screens can produce conflicting results. We organize data into tiered scorecards that connect physical quality, functional activity, stability, and delivery goal alignment.
We review your payload type, target cell or tissue goal, available material amount, preferred readouts, and existing formulation data. A screening matrix is then designed around lipid composition, formulation process variables, and decision thresholds.
LNP candidates are prepared under controlled multi-condition settings. Initial quality checks include particle size, PDI, zeta potential when needed, encapsulation efficiency, visible stability, and recovery.
Candidates passing first-pass quality criteria are tested in selected activity, uptake, intracellular delivery, and stability assays. For deeper physical profiling, projects can integrate particle size, PDI, surface charge, encapsulation, and morphology comparison as needed.
We deliver a ranking report with formulation composition, screening conditions, assay outputs, pass/fail criteria, comparative plots, and recommended next-step candidates for confirmation or optimization.
Challenge: A biotech team had a benchmark LNP that delivered a short reporter mRNA efficiently, but the activity dropped sharply after switching to a 2.7 kb program mRNA with higher secondary structure. The client needed a screening campaign that used limited RNA material while identifying compositions that maintained particle quality and expression.
Screening Design: BOC Sciences built a 48-condition library using six ionizable lipid structures, two helper lipid backgrounds, two PEG-lipid percentages, and two N/P ratio settings. Each formulation was prepared in low-volume format and filtered by size < 120 nm, PDI < 0.20, encapsulation efficiency > 85%, and no visible aggregation after dilution.
Solution: Initial screening showed that the original helper lipid background produced acceptable encapsulation but weak protein expression. We then compared cone-shaped helper lipid enrichment and a reduced PEG-lipid level in the top ionizable lipid group. The best-performing subgroup showed stronger cell-associated uptake and improved endosomal release indicators without increasing size dispersion. Three candidates were advanced to confirmation testing using freshly prepared LNPs and the same RNA lot.
Result: The lead formulation produced a 5.6-fold increase in expression compared with the starting benchmark while maintaining 91-94% encapsulation efficiency and PDI values between 0.11 and 0.16 across three repeats. The client received a ranked shortlist of three LNP compositions with recommended follow-up process variables.
Challenge: A tissue delivery optimization project required a lipid screen that could reduce liver-dominant signal while improving lung-associated expression from an RNA payload. The client had strong total delivery but poor target-to-liver balance in exploratory in vivo imaging and needed a composition-focused path forward.
Screening Design: BOC Sciences designed a 72-formulation panel that varied ionizable lipid pKa range, cholesterol ratio, PEG-lipid anchor length, and helper lipid identity. First-pass QC removed 19 formulations with PDI > 0.25, size drift > 20% after 24 hours, or encapsulation efficiency below the project threshold.
Solution: The remaining candidates were evaluated through a staged readout cascade: in vitro expression in lung-relevant cells, serum-containing stability comparison, and ex vivo tissue signal analysis in a research model. The data showed that high expression in cells did not always predict improved tissue selectivity. Candidates with moderate expression but better colloidal stability and lower PEG-lipid retention produced more favorable target-to-liver ratios.
Result: Four candidates were shortlisted. The best composition improved the lung-to-liver signal ratio by 3.1-fold compared with the client's starting formulation while keeping mean particle size within 75-95 nm and encapsulation efficiency above 88%. The final report identified the lipid variables most associated with the improved distribution profile and suggested two confirmatory formulation windows.
Payload-Centered Screening DesignWe do not assume that one benchmark LNP will work across all payloads. Screening variables are selected based on RNA size, charge density, structural sensitivity, cargo mechanism, and target readout.
Multi-Parameter RankingWe integrate size, PDI, encapsulation, activity, uptake, stability, and tissue-facing indicators into a clear scorecard so clients can select candidates based on evidence rather than a single endpoint.
Low-Volume Screening CapabilityMiniaturized workflows help conserve rare lipids, expensive RNA, and early-stage payload material while still enabling meaningful comparisons across broad lipid composition spaces.
Mechanistic Follow-Up OptionsWhen two candidates show similar activity but different quality profiles, we can add endosomal escape, intracellular localization, release, stability, and morphology readouts to clarify the mechanism.
Smooth Transition to OptimizationShortlisted leads can move into process refinement through LNP process optimization, allowing formulation variables and mixing parameters to be refined after the library screen.
LNP lipid library screening evaluates how different ionizable lipids and helper lipid compositions influence the performance of lipid nanoparticle formulations. For nucleic acid payloads such as mRNA, siRNA, ASO, or plasmid DNA, even small structural differences in the ionizable lipid head group, linker, tail architecture, or apparent pKa can significantly affect encapsulation, particle formation, endosomal escape, and cellular activity. A well-designed screening program compares candidate lipids under controlled preparation conditions and integrates particle size, PDI, zeta potential, encapsulation efficiency, payload protection, colloidal stability, and functional readouts. This allows researchers to move beyond trial-and-error formulation work and identify lipid chemistries that are better aligned with their specific cargo type, target cell model, and downstream development objectives.
A comprehensive LNP lipid library screening study usually examines both composition-related and process-related parameters. Composition variables may include ionizable lipid type, helper phospholipid, cholesterol content, PEG-lipid molar percentage, N/P ratio, lipid-to-RNA ratio, and buffer conditions. Process variables may include mixing ratio, flow rate, total lipid concentration, aqueous phase pH, and post-formulation processing steps. Analytical readouts commonly include hydrodynamic diameter, PDI, zeta potential, encapsulation efficiency, RNA integrity, serum stability, aggregation tendency, and release or leakage behavior. Functional evaluation can further compare cellular uptake, protein expression, gene silencing, or reporter activity in relevant cell models. BOC Sciences can help design tiered screening strategies that connect physical nanoparticle quality with biological performance, enabling clients to select candidates based on balanced formulation behavior rather than a single isolated metric.
The selection of a lipid library depends on the payload, target application, preferred particle profile, and amount of prior formulation knowledge available. For early discovery projects, a broad and chemically diverse ionizable lipid library may be used to explore multiple head groups, linker chemistries, hydrophobic tail structures, and degradability patterns. For projects with an existing lead formulation, a more focused lipid library may be preferred to compare structural analogs or optimize helper lipid combinations. The cargo type is also important: mRNA formulations may require strong payload protection and efficient cytosolic delivery, while siRNA formulations may place greater emphasis on silencing potency and formulation stability. BOC Sciences can tailor lipid library selection around customer-provided project goals, helping teams decide whether they need exploratory screening, focused lead optimization, or comparative benchmarking of selected lipid candidates.
Multiple screening rounds are often needed because LNP performance is controlled by interacting variables rather than one dominant factor. A lipid candidate may show high encapsulation efficiency but poor cellular activity, while another may generate strong functional output but have less favorable particle size or stability. An initial screening round can identify promising lipid structures and remove poorly performing candidates. A second round can refine lipid ratios, PEG-lipid content, N/P ratio, and preparation conditions. A final validation round can compare top candidates under repeated preparation and more application-relevant evaluation conditions. This staged approach provides a clearer understanding of structure–formulation–function relationships and reduces the risk of choosing a candidate based on an unstable or non-reproducible result. BOC Sciences supports this process with integrated formulation preparation, physicochemical characterization, and functional assay design.
BOC Sciences provides LNP lipid library screening services designed to help pharmaceutical and biotechnology researchers identify suitable lipid candidates and formulation directions for nucleic acid and other advanced delivery projects. Our workflow can include candidate lipid selection, microfluidic LNP preparation, formulation matrix design, particle characterization, encapsulation analysis, payload protection assessment, stability comparison, and cell-based functional evaluation. Instead of simply ranking formulations by one endpoint, we help clients interpret the combined data set to understand why certain lipid structures perform better in a given system. This is especially useful when customers need to compare multiple ionizable lipids, optimize helper lipid ratios, troubleshoot poor encapsulation, or improve functional delivery. The goal is to provide actionable formulation insight that supports more efficient nanoparticle development and better-informed candidate selection.
